Setmelanotide
Imcivree, RM-493
An MC4 receptor agonist approved for obesity caused by specific broken genes, and a demonstration that the melanocortin system controls hunger directly.
FDA-approved
FDA-approved as Imcivree for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency, and for Bardet-Biedl syndrome. An indication in acquired hypothalamic obesity has been studied in the TRANSCEND programme.
What it is
Setmelanotide is an agonist at the melanocortin-4 receptor, the node in the hypothalamus where leptin's satiety signal is actually read. Leptin binds its receptor, POMC neurons fire, POMC is cleaved into alpha-MSH, and alpha-MSH activates MC4R to suppress appetite.
Break any step in that chain and the signal never arrives. The person experiences relentless hunger from early childhood and becomes severely obese, and no amount of dietary advice addresses the problem because the problem is a missing message.
Setmelanotide delivers the message at the last step, downstream of whatever is broken.
Why it matters beyond the people who can take it
This is the cleanest demonstration in medicine that obesity can be a specific signalling defect rather than a behavioural failure.
The approved indications are narrow and genetically defined: POMC, PCSK1 or LEPR deficiency, and Bardet-Biedl syndrome. Those are rare conditions. In them, the drug produces large and sustained weight loss and, in the accounts that come out of these trials, a reduction in hunger that patients and families describe as the more important change.
The TRANSCEND programme extended the logic to acquired hypothalamic obesity, where the MC4R pathway is damaged by a tumour or its treatment rather than by a germline mutation. Same broken circuit, different cause.
Where it sits among the melanocortins
This site now carries four compounds acting on this receptor family, and they separate cleanly by selectivity and by what got approved.
- Setmelanotide targets MC4R for appetite, and is approved for genetic obesity.
- Bremelanotide targets MC4R for sexual desire, and is approved as Vyleesi.
- Afamelanotide targets MC1R for pigmentation, and is approved as Scenesse.
- Melanotan-2 hits all of them indiscriminately and is approved nowhere.
The overlapping side effects are informative. Setmelanotide causes pigmentation and spontaneous erections because MC4R agonism is not perfectly isolated from the rest of the family. That is the same crosstalk that makes melanotan-2 do several things at once, except here it is a side effect of a targeted drug rather than the entire pharmacology.
Practical notes
- It is not a general obesity drug and was never proposed as one. In common polygenic obesity, the MC4R pathway is intact and there is nothing for setmelanotide to restore.
- The depression labelling is worth taking seriously. Melanocortin signalling in the brain is not confined to appetite, and this appears in the approved label rather than in speculation.
- Skin surveillance is part of the treatment. Any chronic melanocortin agonist warrants it, and here it is built into the protocol.
Side effects and warning signs
Commonly reported
- Skin hyperpigmentation and darkening of moles, which follows from MC1 receptor activity
- Injection-site reactions
- Nausea
- Spontaneous erections in men and changes in sexual arousal, from the same receptor family bremelanotide acts on
- Depression and suicidal ideation, which appear in the labelling
Stop and get medical help
- New or changing pigmented lesions. Full skin examination before starting and periodically afterwards is part of the approved labelling
- New or worsening depression or suicidal thinking, which is a labelled risk rather than a theoretical one
Sources
From the community
Discussion for this compound concentrates in r/Semaglutide.
No threads cached yet.
Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.